Lexeo Therapeutics Inc. has announced a new compensation agreement with Dr. Adler, who has stepped down from his role as Head of Research effective February 1, 2026. Under the Transition and Consulting Agreement, Dr. Adler will provide advisory services to the company until the earlier of July 31, 2026, or termination of the agreement. He will receive up to $62,500 in monthly installments during this period, and his service-vesting equity awards will continue to vest. Additionally, Dr. Adler's deadline to exercise any vested stock options will be extended to six months following the end of the transition period. Upon completion of the transition period and execution of a supplemental release of claims, he will receive a lump sum payment of $1,000.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lexeo Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-039425), on February 05, 2026, and is solely responsible for the information contained therein.